DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for Familial gastric cancer — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleFamilial gastric cancer maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for familial gastric cancer is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
KRas proto-oncogene, GTPase (KRAS) — KRAS is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet gnpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7VVB · 1.7 Å · ligand PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER (GNP). Experimental structure, not a prediction.
What the evidence adds up to
A 2014 meta-analysis of five studies including 2,030 patients found no significant difference in overall survival after gastric cancer surgery based on any family history of cancer (hazard ratio 0.83, 95% confidence interval 0.50–1.38). However, subgroup analyses showed that patients with a first-degree family history of any cancer (HR 0.74, 0.60–0.93) and those with a family history specifically of gastric cancer (HR 0.56, 0.41–0.76) had better overall survival. The authors note that previous studies had generated conflicting evidence on this question.
A 2022 cross-sectional study using Korean Genome and Epidemiology Study data examined 930 participants with a self-reported personal history of gastric cancer and 37,200 matched controls. After adjusting for confounders, the odds ratios for gastric cancer were 1.80 (95% CI 1.38–2.34) for a history in the father, 1.95 (1.42–2.69) for the mother, and 2.98 (2.31–3.83) for a sibling. The authors conclude that a history of gastric cancer in siblings is strongly associated with increased risk. A 2012 single-centre study of 724 patients in southern China states that 5–10% of gastric cancer cases have a familial association but provides no survival or response data.
A 2003 review notes that chemotherapy benefits gastric cancer patients and that a large randomised trial showed an advantage for adding docetaxel to 5-fluorouracil and cisplatin. The review does not report survival or response rates for any regimen and does not address familial gastric cancer specifically. What remains missing is prospective data on whether familial gastric cancer patients respond differently to specific chemotherapy regimens, and whether genetic stratification could guide treatment in this subgroup. No trial has yet tested a drug specifically in familial gastric cancer patients.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Asian Pacific Journal of Cancer Prevention · 2014 · 14 citations · open access
Family History and Survival of Patients with Gastric Cancer: A Meta-Analysis
AbstractBACKGROUND: Previous studies have generated conflicting evidence regarding associations between family history and survival after gastric cancer surgery. In this study, we investigated this question using a meta-analysis. MATERIALS AND METHODS: To identify relevant studies, PubMed and Embase databases were searched up to June 2013. Two reviewers independently assessed search results and data extraction of included studies. Hazard ratios (HRs) and 95% confidence intervals (CIs) for overall survival (OS) were calculated based on fixed- or random- effects models. Homogeneity of effects across studies was assessed using x2 test statistics and quantified by I2. RESULTS: A total of five studies were selected according to the inclusion criteria. The total number of patients included was 2,030, which ranged from 145 to 598 per study. There was no significant difference in OS by family history of cancer (HR=0.83, 95%CIs=0.50-1.38), but subgroup analysis of patients with a first-degree family history of cancer (HR=0.74, 95%CIs=0.60-0.93) and gastric cancer family history (HR=0.56, 95%CIs=0.41-0.76) tended to show better OS in these patients. CONCLUSIONS: This meta-analysis suggests that a first-degree family history of cancer or gastric cancer family history is associated with better survival of gastric cancer patients after surgery, after a systematic review of five previous studies. These results can be applied by clinicians when counselling patients regarding their risk of death from gastric cancer. Further study is needed to investigate the underlying mechanism between family history and survival in gastric cancer patients.
Journal of Oncology · 2012 · 7 citations · open access
Analysis on the Clinical and Pathological Features and Prognosis of Familial Gastric Cancer in South China Population: A Single-Center Study of 724 Patients
AbstractGastric cancer is the second most common cause of cancer death worldwide. It is estimated that 5-10% of gastric cancer cases have a familial association; however, knowledge concerning the clinical, pathological features and prognosis to familial gastric cancer is currently limited. To our best knowledge, this is the largest number of single center patients reported in southern China. Our research can help these rare families to obtain optimal treatment in the future. Our work is supported by Union Hospital of Fujian Medical University.
Association between gastric cancer and the family history of gastric cancer: a cross-sectional study using Korean Genome and Epidemiology Study data.
AbstractOBJECTIVE: The risk of gastric cancer based on a family history of gastric cancer remains unclear. The purpose of this study was to investigate the relationship between gastric cancer and family history of gastric cancer within a large cohort in Korea. METHODS: In total 211 708 participants were recruited in the Korean Genome and Epidemiology Study during 2001-2013, and divided into a group with a self-reported personal history of gastric cancer ( n = 930) and a 1:40 matched control group ( n = 37 200). We examined the family history of gastric cancer in first-degree relatives for cross-sectional analysis. Logistic regression was used to estimate the odds ratios (ORs) of gastric cancer according to family history, using four models that were adjusted for different confounding variables, including the interaction among a family history of gastric cancer. RESULTS: After matching the two groups for age and sex, the gastric cancer group had a significantly higher proportion of family history in each relative than the controls ( P < 0.001). In the adjusted model, the ORs [95% confidence interval (CI)] for gastric cancer with a history of an affected father, mother and sibling were 1.80 (1.38-2.34), 1.95 (1.42-2.69) and 2.98 (2.31-3.83), respectively, compared with those in the control group. There was no statistically significant interaction among a family history of gastric cancer in each relative. CONCLUSION: A history of gastric cancer in siblings, among first-degree relatives, is strongly associated with an increased risk of gastric cancer. Regular follow-up and early treatment are recommended for those with a family history of gastric cancer.
American Journal of Clinical Oncology · 1999 · 4 citations
North Central Cancer Treatment Group Phase II Study of 5-Fluorouracil and High-Dose Levamisole for Gastric and Gastroesophageal Cancer Using Survival as the Primary Endpoint of Efficacy
AbstractAt present there is no established standard chemotherapy for advanced gastric cancer. Combination regimens have yielded response rates at times exceeding 50% but with no improvement in survival compared to single agents. This study examined the role of 5-fluorouracil and high-dose levamisole in a phase II setting using survival as the main endpoint. Patients with advanced carcinomas of the stomach or gastroesophageal junction were treated with 5-fluorouracil, 450 mg/m2 IV days 1 to 5, and levamisole, 100 mg/m2 orally three times daily on days 1 to 3, and 50 mg/m2 tid days 4 to 5 every 5 weeks. To allow more rapid accrual and to study a population that more accurately reflects the makeup of patients treated in clinical practice, patients with both measurable and nonmeasurable disease were entered in this study. Two of fifteen (13%) patients with measurable disease experienced a partial response to treatment. The adjusted 1-year survival rate for the 44 patients entered was 29.6%, which is similar to the historical 1-year survival of 30% observed in a group of nearly 400 patients treated in prior North Central Cancer Treatment Group studies. This regimen offers no improvement in therapeutic activity for advanced gastric cancer. This study design, however, allows rapid screening of phase II regimens in patients who would usually be candidates for phase III trials.
Annals of Cancer Research and Therapy · 2003 · 0 citations · open access
TREATMENT OF GASTRIC CANCER FOR SURVIVAL-STRATEGIES IN THE USA AND JAPAN
AbstractChemotherapy has been shown to benefit patients with gastric cancer. The most effective regimen remains controversial. A recent large randomized clinical trial has demonstrated an advantage with the addition of docetaxel to 5-fluorouracil and cisplatin. New agents are being incorporated into the treatment of gastric cancer to maximize efficacy with minimal additional toxicity. Future clinical trials will explore the use of new agents as well as genetic polymorphisms that may influence drug metabolism and efficacy.
AbstractThe etiology of familial gastric cancer (FGC) are E-cadherin (CDH1) mutations,helicobacter pylori infection,etc.The median age of patients with FGC is 50-65 years old.The male-female sex ratio is 2 ∶ 1.The most of tumors of FGC locate in distal stomach and present diffuse type in histological classification.It is reported that the people who has a family history of gastric cancer especially for those parents has an increased risk of gastric cancer.It is difficult to find FGC in early stage by current technology.The preventive methods include eradication of helicobacter pylori and prophylactic total gastrectomy,etc.
Key words:
Stomach neoplasms; Family; Heredity
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
